Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists
AssigneeThe University of Chicago
InventorsRussell Z. Szmulewitz, Suzanne D. Conzen
Life of this patent
Estimating the term…
Abstract
Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
Claims20
A method of treating castration-resistant prostate cancer in a patient, comprising:
- a) administering to said patient a therapeutically effective amount of a glucocorticoid receptor (GR) antagonist;
- and
- b) administering an anticancer therapy,
- whereby said castration-resistant prostate cancer is treated in the patient.
A method of treating castration-resistant prostate cancer in a patient, the method comprising:
- a) administering a first anticancer therapy to said patient;
- b) administering a therapeutically effective amount of a GR antagonist to the patient;
- and
- c) administering a second anticancer therapy to the patient after the GR antagonist is administered to the patient,
- whereby said castration-resistant prostate cancer is treated in the patient.
A method of killing castration-resistant prostate cancer cells in a patient comprising:
- administering to said patient an effective amount of a combination of a glucocorticoid receptor (GR) antagonist and an anticancer therapy,
- wherein said combination comprises administration of said GR antagonist to the patient prior to, concurrently with, or after, the administration of said anticancer therapy to the patient, whereby said castration-resistant prostate cancer cells are killed in the patient.
Dependencies are inferred from the claim text.